Have a feature idea you'd love to see implemented?
Let us know!
CRBP Corbus Pharmaceuticals Holdings Inc
Price (delayed)
$13.14
Market cap
$160.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.67
Enterprise value
$143.56M
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is
Highlights
The quick ratio has soared by 124% QoQ
CRBP's debt has dropped by 84% year-on-year and by 76% since the previous quarter
Corbus Pharmaceuticals Holdings's net income has increased by 18% YoY but it has decreased by 11% from the previous quarter
Key stats
What are the main financial stats of CRBP
Market
Valuations
Earnings
Shares outstanding
12.18M
Market cap
$160.04M
Enterprise value
$143.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.05
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$38.7M
EBIT
-$36.78M
EBITDA
-$36.18M
Free cash flow
-$36.86M
Per share
Balance sheet
Liquidity
EPS
-$4.67
EPS diluted
-$4.67
Free cash flow per share
-$3.07
Book value per share
$12.5
Revenue per share
$0
TBVPS
$13.66
Total assets
$164.17M
Total liabilities
$13.67M
Debt
$3.61M
Equity
$150.5M
Working capital
$149.27M
Debt to equity
0.02
Current ratio
13.84
Quick ratio
13.77
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-32.9%
Return on equity
-42.3%
Return on invested capital
-40.9%
Return on capital employed
-24.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRBP stock price
How has the Corbus Pharmaceuticals Holdings stock price performed over time
Intraday
-0.23%
1 week
-1.43%
1 month
-26.92%
1 year
143.33%
YTD
117.55%
QTD
-36.31%
Financial performance
How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$46.22M
Net income
-$38.7M
Gross margin
N/A
Net margin
N/A
Corbus Pharmaceuticals Holdings's net income has increased by 18% YoY but it has decreased by 11% from the previous quarter
The operating income is down by 15% since the previous quarter
Growth
What is Corbus Pharmaceuticals Holdings's growth rate over time
Valuation
What is Corbus Pharmaceuticals Holdings stock price valuation
P/E
N/A
P/B
1.05
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Corbus Pharmaceuticals Holdings's EPS has surged by 58% YoY and by 19% QoQ
CRBP's P/B is 91% below its 5-year quarterly average of 11.4
The company's equity rose by 20% QoQ
Efficiency
How efficient is Corbus Pharmaceuticals Holdings business performance
The ROE has soared by 87% YoY and by 35% QoQ
The ROA has soared by 66% YoY and by 20% from the previous quarter
CRBP's return on invested capital has surged by 60% year-on-year and by 25% since the previous quarter
Dividends
What is CRBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRBP.
Financial health
How did Corbus Pharmaceuticals Holdings financials performed over time
The quick ratio has soared by 124% QoQ
Corbus Pharmaceuticals Holdings's current ratio has surged by 124% QoQ
CRBP's debt is 98% smaller than its equity
CRBP's debt to equity has dropped by 100% year-on-year and by 83% since the previous quarter
CRBP's debt has dropped by 84% year-on-year and by 76% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.